Reportlinker Adds Chronic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Apr 14, 2011, 06:41 ET
NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Chronic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Chronic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Chronic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Chronic Pain Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chronic Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Chronic Pain Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chronic Pain Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Chronic Pain Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chronic Pain Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Chronic Pain Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Chronic Pain Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chronic Pain Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Chronic Pain Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Chronic Pain Therapeutics: Introduction 6
2.1 Disease Overview 6
2.1.1 Types of Chronic Pain 7
2.2 Epidemiology 7
2.3 Etiology and Pathophysiology 8
2.4 Signs and Symptoms 10
2.5 Diagnosis 10
2.5.1 Commonly Used Pain Scales 10
2.5.2 Commonly Used Diagnosis Tests 11
2.6 Treatment and Management Options 12
2.7 GlobalData Pipeline Report Guidance 13
3 Chronic Pain Therapeutics: Market Characterization 14
3.1 Chronic Pain Therapeutics Market Size (2005–2010) – Global 14
3.2 Chronic Pain Therapeutics Market Forecast (2010–2017) – Global 15
3.3 Chronic Pain Therapeutics Market Size (2005–2010) – The US 16
3.4 Chronic Pain Therapeutics Market Forecast (2010–2017) – The US 17
3.5 Chronic Pain Therapeutics Market Size (2005–2010) – France 18
3.6 Chronic Pain Therapeutics Market Forecast (2010–2017) – France 19
3.7 Chronic Pain Therapeutics Market Size (2005–2010) – Germany 20
3.8 Chronic Pain Therapeutics Market Forecast (2010–2017) – Germany 21
3.9 Chronic Pain Therapeutics Market Size (2005–2010) – Italy 22
3.10 Chronic Pain Therapeutics Market Forecast (2010–2017) – Italy 23
3.11 Chronic Pain Therapeutics Market Size (2005–2010) – Spain 24
3.12 Chronic Pain Therapeutics Market Forecast (2010–2017) – Spain 25
3.13 Chronic Pain Therapeutics Market Size (2005–2010) – The UK 26
3.14 Chronic Pain Therapeutics Market Forecast (2010–2017) – The UK 27
3.15 Chronic Pain Therapeutics Market Size (2005–2010) – Japan 28
3.16 Chronic Pain Therapeutics Market Forecast (2010–2017) – Japan 29
3.17 Drivers and Barriers for the Chronic Pain Therapeutics Market 30
3.17.1 Drivers for the Chronic Pain Therapeutics Market 30
3.17.2 Barriers for the Chronic Pain Therapeutics Market 30
3.18 Opportunity and Unmet Need Analysis 31
3.19 Key Takeaway 32
4 Chronic Pain Therapeutics: Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profiles for the Major Marketed Products in the Chronic Pain Therapeutics Market 34
4.3.1 Celebrex (celecoxib) 34
4.3.2 Voltaren Gel (diclofenac sodium) 35
4.3.3 Cymbalta (duloxetine hydrochloride) 36
4.3.4 Lyrica (pregabalin) 37
4.3.5 Morphine 38
4.4 Key Takeaway 39
5 Chronic Pain Therapeutics: Pipeline Assessment 40
5.1 Overview 40
5.2 Strategic Pipeline Assessment 40
5.3 Chronic Pain Therapeutics Pipeline – Pipeline by Phases of Development 41
5.3.1 Chronic Pain Therapeutics – Regulatory Filed Products 41
5.3.2 Chronic Pain Therapeutics – Phase III Pipeline 42
5.3.3 Chronic Pain Therapeutics – Phase II Pipeline 43
5.3.4 Chronic Pain Therapeutics – Phase I Pipeline 44
5.3.5 Chronic Pain Market – Discovery and Pre-Clinical Pipeline 45
5.3.6 Technology Trends Analytic Framework 46
5.4 Chronic Pain Therapeutics Market – Clinical Pipeline by Mechanism of Action 48
5.5 Chronic Pain Therapeutics – Promising Drugs Under Clinical Development 49
5.6 Molecule Profile for Promising Drugs Under Clinical Development 49
5.6.1 AVP-923 (Zenvia) 49
5.6.2 Tetrodotoxin for cancer-related pain (Tectin) 50
5.6.3 2PX (topical strontium chloride hexahydrate) 51
5.7 Key Takeaway 52
6 Chronic Pain Therapeutics: Clinical Trials Mapping 53
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 53
6.2 Clinical Trials by Phase 54
6.3 Clinical Trials by Trial Status 55
6.4 Prominent Sponsors 56
6.5 Top Companies Participating in Chronic Pain Therapeutics Clinical Trials 58
7 Strategic Assessment 60
7.1 Key Events Impacting the Future Market 60
7.2 Chronic Pain Therapeutics: Implications for Future Market Competition 61
8 Chronic Pain Therapeutics: Future Players 62
8.1 Introduction 62
8.2 Company Profiles 63
8.2.1 Pfizer Inc. 63
8.2.2 Grunenthal GmbH 68
8.2.3 Transdel Pharmaceuticals, Inc. 70
8.2.4 WEX Pharmaceuticals 72
8.2.5 Avanir Pharmaceuticals 74
8.2.6 Cephalon, Inc. 75
8.2.7 Elite Pharmaceuticals 79
8.2.8 Endo Pharmaceuticals 80
8.2.9 Depomed Inc. 83
8.2.10 Other Companies in the Chronic Pain Therapeutics Market 85
9 Chronic Pain Therapeutics: Licensing and Partnership Deals 89
10 Chronic Pain Therapeutics: Appendix 95
10.1 Market Definitions 95
10.2 Abbreviations 95
10.3 Research Methodology 97
10.3.1 Coverage 97
10.3.2 Secondary Research 97
10.3.3 Forecasting 97
10.3.4 Primary Research 100
10.3.5 Expert Panel Validation 100
10.4 Contact Us 100
10.5 Disclaimer 100
10.6 Bibliography 101
1.1 List of Tables
Table 1: Differentiation of Chronic Pain from Acute Pain 7
Table 2: Chronic Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 14
Table 3: Chronic Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017 15
Table 4: Chronic Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010 16
Table 5: Chronic Pain Therapeutics Market, The US, Forecasts ($bn), 2010–2017 17
Table 6: Chronic Pain Therapeutics Market, France, Revenue ($m), 2005–2010 18
Table 7: Chronic Pain Therapeutics Market, France, Forecasts ($m), 2010–2017 19
Table 8: Chronic Pain Therapeutics Market, Germany, Revenue ($bn), 2005–2010 20
Table 9: Chronic Pain Therapeutics Market, Germany, Forecasts ($bn), 2010–2017 21
Table 10: Chronic Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 22
Table 11: Chronic Pain Therapeutics Market, Italy, Forecasts ($m), 2010–2017 23
Table 12: Chronic Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 24
Table 13: Chronic Pain Therapeutics Market, Spain, Forecasts ($m), 2010–2017 25
Table 14: Chronic Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 26
Table 15: Chronic Pain Therapeutics Market, The UK, Forecasts ($m), 2010–2017 27
Table 16: Chronic Pain Therapeutics Market, Japan, Revenue ($bn), 2005–2010 28
Table 17: Chronic Pain Therapeutics Market, Japan, Forecasts ($bn), 2010–2017 29
Table 18: Clinical Trials of Cymbalta 36
Table 19: Clinical Trials of Lyrica 37
Table 20: Chronic Pain Therapeutics, Regulatory Filed Products, 2011 41
Table 21: Chronic Pain Therapeutics, Phase III Pipeline, 2011 42
Table 22: Chronic Pain Therapeutics, Phase II Pipeline, 2011 43
Table 23: Chronic Pain Therapeutics, Phase I Pipeline, 2011 44
Table 24: Chronic Pain Therapeutics, Discovery and Pre-Clinical Pipeline, 2011 45
Table 25: Chronic Pain Therapeutics – Most Promising Drugs Under Clinical Development, 2011 49
Table 26: Chronic Pain Therapeutics, Clinical Trials by Country, 2011 53
Table 27: Chronic Pain Therapeutics - Clinical Trials by Phase, 2011 54
Table 28: Chronic Pain Therapeutics, Clinical Trials by Status (%), 2011 55
Table 29: Chronic Pain Therapeutics, Prominent Sponsors, 2011 57
Table 30: Chronic Pain Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 59
Table 31: Pfizer Inc., Pain Management, Pipeline, 2011 65
Table 32: Pfizer, Inc., Deals, 2010–2011 65
Table 33: Grunenthal GmbH, Pain Management, Pipeline, 2011 68
Table 34: Grunenthal GmbH, Deals, 2010-11 69
Table 35: Transdel Pharmaceuticals – Pain Management, Pipeline, 2011 71
Table 36: Transdel Pharmaceuticals, Inc. – Deals, 2010-11 71
Table 37: WEX Pharmaceuticals, Pain Management Pipeline, 2011 73
Table 38: WEX Pharmaceuticals Inc., Deals , 2010-11 73
Table 39: Avanir Pharmaceuticals – Pain Management, Pipeline, 2011 74
Table 40: Avanir Pharmaceuticals – Deals, 2009-2010 75
Table 41: Cephalon, Inc., Pain Management Pipeline, 2011 76
Table 42: Transdel Pharmaceuticals, Inc., Deals, 2010–2011 77
Table 43: Elite Pharmaceuticals, Pain Management, Pipeline, 2011 80
Table 44: Elite Pharmaceuticals, Deals, 2010–2011 80
Table 45: Endo Pharmaceuticals, Pain Management, Pipeline, 2011 82
Table 46: Endo Pharmaceuticals, Deals, 2009-11 82
Table 47: Depomed Inc, Pain Management, Pipeline, 2011 84
Table 48: Depomed, Inc, Deals, 2009–2011 84
Table 49: Chronic Pain Therapeutics Market, Future Players 85
Table 50: Chronic Pain Therapeutics, Global, Deals, 2009-2011 89
1.2 List of Figures
Figure 1: Classification of Chronic Pain and Representative Indications 6
Figure 2: Pathophysiology of Nociceptive Pain 8
Figure 3: Pathophysiology of Neuropathic Pain 9
Figure 4: Pain Measurement Scale – Numeric Rating Scale 10
Figure 5: Pain Measurement Scale – Visual Analog Scale 11
Figure 6: Pain Measurement Scale – Faces Rating Scale 11
Figure 7: Chronic Pain Relief Treatment Chart, 2011 12
Figure 8: Chronic Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 14
Figure 9: Chronic Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017 15
Figure 10: Chronic Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010 16
Figure 11: Chronic Pain Therapeutics Market, The US, Forecast ($bn), 2010–2017 17
Figure 12: Chronic Pain Therapeutics Market, France, Revenue ($m), 2005–2010 18
Figure 13: Chronic Pain Therapeutics Market, France, Forecast ($m), 2010–2017 19
Figure 14: Chronic Pain Therapeutics Market, Germany, Revenue ($bn), 2005–2010 20
Figure 15: Chronic Pain Therapeutics Market, Germany, Forecast ($bn), 2010–2017 21
Figure 16: Chronic Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 22
Figure 17: Chronic Pain Therapeutics Market, Italy, Forecast ($m), 2010–2017 23
Figure 18: Chronic Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 24
Figure 19: Chronic Pain Therapeutics Market, Spain, Forecast ($m), 2010–2017 25
Figure 20: Chronic Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 26
Figure 21: Chronic Pain Therapeutics Market, The UK, Forecast ($m), 2010–2017 27
Figure 22: Chronic Pain Therapeutics Market, Japan, Revenue ($bn), 2005–2010 28
Figure 23: Chronic Pain Therapeutics Market, Japan, Forecast ($bn), 2010–2017 29
Figure 24: Opportunity and Unmet Need in the Chronic Pain Therapeutics Market, 2010 31
Figure 25: Chronic Pain Therapeutics, Strategic Competitor Assessment, 2010 33
Figure 26: Chronic Pain Therapeutics – Pipeline by Phase of Development, 2011 41
Figure 27: Chronic Pain Therapeutics, Technology Trends Analytics Framework, 2011 46
Figure 28: Chronic Pain Therapeutics, Technology Trends Analytics Framework, Description, 2011 47
Figure 29: Chronic Pain Therapeutics, Pipeline by Mechanism of Action (%), 2011 48
Figure 30: Chronic Pain Therapeutics, Clinical Trials by Country, 2011 53
Figure 31: Chronic Pain Therapeutics, Clinical Trials by Phase (%), 2011 54
Figure 32: Chronic Pain Therapeutics, Clinical Trials by Status (%), 2011 55
Figure 33: Chronic Pain Therapeutics, Overall Sponsors (%), 2011 56
Figure 34: Chronic Pain Therapeutics, Prominent Sponsors (%), 2011 57
Figure 35: Chronic Pain Therapeutics, Top Companies Participating in Clinical Trials, 2011 58
Figure 36: Chronic Pain Therapeutics Market, Drivers and Restraints 2011 60
Figure 37: Implications for Future Market Competition in the Chronic Pain Market, 2011 61
Figure 38: Chronic Pain Therapeutics Market, Pipeline by Company, 2011 62
Figure 39: GlobalData Market Forecasting Model 99Pfizer Inc.
Grunenthal GmbH
Transdel Pharmaceuticals, Inc.
WEX Pharmaceuticals
Avanir Pharmaceuticals
Cephalon, Inc.
Elite Pharmaceuticals
Endo Pharmaceuticals
Depomed Inc.
To order this report:
: Chronic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker